# Sotagliflozin Versus Empagliflozin Added to Metformin for Glycemic Control in Type 2 Diabetes

Study · id `cardio:ct-nct07939750` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07939750](<https://clinicaltrials.gov/study/NCT07939750>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07939750

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 140 participants.

## Technical summary

Registry record NCT07939750. Randomized; single masking; primary purpose treatment. Start 2026-12-01 (anticipated); primary completion 2027-12-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 140 participants (planned count; ClinicalTrials.gov record NCT07939750, source copy `cardio:ctgov-nct07939750-2026-11-16`, retrieved 2026-11-18)
- Planned start: 2026-12-01 (anticipated) (ClinicalTrials.gov record NCT07939750, source copy `cardio:ctgov-nct07939750-2026-11-16`, retrieved 2026-11-18)
- Primary completion: 2027-12-01 (anticipated) (ClinicalTrials.gov record NCT07939750, source copy `cardio:ctgov-nct07939750-2026-11-16`, retrieved 2026-11-18)
- Completion: 2028-01-31 (anticipated) (ClinicalTrials.gov record NCT07939750, source copy `cardio:ctgov-nct07939750-2026-11-16`, retrieved 2026-11-18)
- Countries: Pakistan (ClinicalTrials.gov record NCT07939750, source copy `cardio:ctgov-nct07939750-2026-11-16`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07939750-2026-11-16`, retrieved 2026-11-18)

## The registry's words

- Brief title: Sotagliflozin Versus Empagliflozin Added to Metformin for Glycemic Control in Type 2 Diabetes
- Condition: Type 2 Diabetes Mellitus (DM)
- Intervention (Drug): Sotagliflozin
- Intervention (Drug): Empagliflozin (oral)
- Intervention (Drug): Metformin
- Lead sponsor: Allied Hospital Faisalabad
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 9a344812a9cd09423d6ded3554472c3afbd55c2ba7d424c31fc4f3725f05069d
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
